ABSI Absci Corporation
ABSI Absci Corporation
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $2.85 · VWAP $5.91 · +39.6% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
2 watchlists
ABSI Price Structure
Loading timeframes…
Peers
Every watchlist ABSI belongs to, members best 30-day change first — ABSI highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Absci furnished its earnings release to the SEC on August 11, 2026 (8-K, Item 2.02) and filed its 10-Q for the quarter ended June 30, 2026 the same day. No figures from these filings are recorded here.
full note →Against street estimates
How ABSI's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about ABSI from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 8 days ago · Oct 9
- Absci Corporation (NASDAQ:ABSI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
- Investor Relations | Absci Corp
- Absci (ABSI) Q2 2026 Earnings Call Transcript - The Motley Fool
- Absci Reports Business Updates and Second Quarter 2026
- Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results | Nasdaq
ABSI research tape
63 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to ABSI.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries